Project Grant R41CA298223
Award Date
12/13/24
Completion Date
11/30/25
Dollars Obligated
$400K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Columbia, SC 29208, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000.00 to Nuago Therapeutics Inc., a self-certified small disadvantaged business, to develop a disease-inducing, short RNA therapeutic to treat ovarian cancer. The award period runs from June 9, 2025 to May 31, 2026. The project aims to advance cancer diagnosis, treatment, and understanding by exploring innovative therapeutic approaches to improve cancer patient outcomes....
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $349,808 to Oncurie Inc. to continue development of a novel targeted radiopharmaceutical for imaging and potential therapy of ovarian cancer. The compound leverages the folate receptor overexpression in ovarian tumors to enable precision imaging, with future plans to incorporate cytotoxic radionuclides for targeted therapy. During the Phase I award period from Sep 2024...
The National Cancer Institute (NCI) awarded a 5-year, $375,134 Project Grant under the Cancer Treatment Research (CFDA 93.395) federal grant program to the University of Colorado-Denver. The grant supports research to reduce off-target accumulation of chemotherapeutic nanomedicines and improve the efficacy of cancer chemotherapy. Key activities include characterizing the immune response that limits nanoparticle delivery to healthy tissues, and exploring the potential to use this response to...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $546,625.00 to the University of Pittsburgh to develop and evaluate a nanoparticle-based immunochemotherapy for the treatment of metastatic colorectal cancer. The key objectives are to: 1) Develop and characterize a nanoparticle platform that can co-deliver siRNA targeting the IRHOM1 protein and a chemotherapy agent (CPT-SAHA) to enhance tumor targeting and immune...
The National Cancer Institute (NCI) awarded a $483,556 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of New Mexico Health Sciences Center (UNM HSC) to investigate the use of toll-like receptor (TLR) agonist-modified mesoporous silica nanoparticles (MSN) for the treatment of peritoneal metastases in ovarian and colorectal cancers. The project aims to define the mechanisms by which intraperitoneal delivery of the modified-MSN leads to tumor eradication, focusing on...
The National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), awarded a $400,000 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Nuago Therapeutics Inc. on September 19, 2024. The goal of this STTR project is to develop an RNA interference-based therapeutic to treat prostate cancer. The therapeutic, termed "NU002", will use lipopolyplex nanoparticles to deliver short interfering RNAs (siRNAs) derived from CAG trinucleotide repeat sequences....
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $371,070 to Resonant Therapeutics, Inc. to develop a novel nectin-targeting antibody-drug conjugate (ADC) for the treatment of ovarian cancer. The funding will be used to refine the target patient population, determine the optimal payload, and establish preclinical dosing for the ADC. This represents an important advancement, as current ADC treatments for ovarian cancer are...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug treatment for inhibiting cancer growth and metastasis, particularly for ovarian, lung, and colon cancers. The research aims to leverage tumor-associated hyperactive membrane-anchored serine proteases on the surface of malignant tumor cells to selectively deliver potent cytotoxins and enhance sensitivity...
This $415,830 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to develop an integrated nanoplasmonic sensing platform termed "Nano-CRISPR" for longitudinal tumor monitoring in ovarian cancer patients. The key products and services to be delivered include: Incorporation of single extracellular vesicle (EV) capture and analysis using plasmonic nanodisk arrays, CRISPR/Cas13a sensors for lysis-free,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $399,970 to Duo Oncology Inc. to develop DUO-207, an ultrasmall nanoparticle formulation designed to improve the delivery and efficacy of combination chemotherapy for advanced pancreatic cancer. The key product being developed under this award is DUO-207, which combines a polymer-conjugated gemcitabine and paclitaxel in a single 14nm nanoparticle. This novel formulation...